Nanoligent, a Barcelona-based biotech developing precision nanodrugs for cancer, raised €2 million in a Series A fundraising round led by Inveready with participation from CDTI via Innvierte, Clave Capital Clave Innohealth, and others.
More on Silicon Canals 1



